

Editorial Board Members' Collection Series: Recent Advancements of HPV Tumors of Head and Neck

Guest Editors:

Dr. Jong Chul Park

Department of Medicine,
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

Dr. Raffaele Addeo

Medical Oncology Unit, San
Giovanni di Dio Hospital, 80027
Frattamaggiore, Naples, Italy

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editors

Although the incidence of smoking-related head and neck cancer (HNSCC) has been declining, that of HPV-mediated HNSCC has been consistently increasing globally for the past few decades, creating an increasing burden on the health system and posing a threat to otherwise healthy individuals. Although the majority of patients with HPV HNSCC are cured, the treatment-induced toxicity remains significant. For those with advanced disease, the treatment options are limited without major therapeutic breakthroughs since the introduction of anti-PD-1 immunotherapy.

In this Special Issue of recent advancements of HPV tumors of head and neck, we welcome original research or review articles on the wide range of topics related to HPV HNSCC, from epidemiology and biology to de-escalation strategies for locally advanced disease, plasma-based detection/surveillance of disease, and novel therapeutics, including HPV-targeting therapeutic vaccines or other novel biologic agents.

